奇信股份(002781.SZ)拟向银行申请不超3.15亿元综合授信额度
格隆汇3月24日丨奇信股份(002781.SZ)公布,公司召开第三届董事会第五十八次会议,审议通过《关于公司向银行申请综合授信额度的议案》。
为促进公司业务拓展,满足公司运营资金需求,公司董事会同意公司向汇丰银行(中国)有限公司深圳分行申请总额不超过人民币3.15亿元的综合授信额度,授信期限为一年。
在以上授信额度内,限额内的授信可分多次循环使用。以上授信额度不等于公司的实际融资金额,实际融资金额应在授信额度内以银行与公司实际发生的融资金额为准。
公司董事会同意授权法定代表人余少雄全权代表公司签署上述授信额度内的全部文书。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.